Prognostic impact of thrombocytosis in resectable non-small cell lung cancer

Abstract

Relationship between thrombocytosis and poor prognosis has been reported in lung cancer. However, the majority of previous studies included many advanced stage and small cell lung cancer patients. Few studies focused on resectable non-small cell lung cancer patients. In the present study, therefore, consecutive 240 non-small cell lung cancer patients who received surgical resection were reviewed retrospectively, and investigated the survival impact of preoperative platelet count. In our results, the frequency of preoperative thrombocytosis was only 5.83% (14/240). The 5-year survival of patients with and without thrombocytosis was 28.87% and 63.73%, respectively. Both univariate and multivariate analyses indicated the independent prognostic impact of thrombocytosis. The present study is the first evaluation of prognostic effect of thrombocytosis in patients with resectable non-small cell lung cancer. Preoperative platelet count was a prognostic factor for resectable non-small cell lung cancer patients.

Elevated Platelets Enhance Cancer Cell Migration, Promote Hematogenous Metastasis and Associate with a Poor Prognosis in Advanced Non-small Cell Lung Cancer Cases

“…The course of cancer is strongly associated with hypercoagulable state. Our study showed that increased platelet count predicted shorter PFS in advanced NSCLC, which was consistent with previous studies (Tomita et al, 2008;Yu et al, 2013). However, the mechanisms responsible for platelet mediated effect on NSCLC prognosis remained unclear so far.…”

“…Regarding NSCLC, Costantini et al demonstrated that NSCLC patients had increased prevalence of thrombocytosis and relative high platelet levels during disease progression (Costantini et al, 1990). Among operable I-III NSCLC patients, those with elevated platelet counts showed an increased risk of disease progression and overall survival (Tomita et al, 2008;Yu et al, 2013). Thrombocytosis was also associated with overall survival in III/IV NSCLC patients (Engan and Hannisdal, 1990).…”

Pretreatment Thrombocytosis as a Prognostic Factor in Women with Gynecologic Malignancies: a Meta-analysis

“…According to the experimental evidence, it suggested that platelets actively promote cancer cell dissemination by protection of circulating cancer cells from immune surveillance, negotiation of cancer-cell arrest in the microvasculature, and stimulation of angiogenesis (Nieswandt et al, 1999;Borsig et al, 2008). Recent studies have addressed the prevalence and prognostic impact of thrombocytosis in various malignancies, including stomach, lung, kidney, uterus, and gynecologic malignancies (Zeimet et al, 1993;Menczer et al, 1998;Tomita et al, 2008;Heras et al, 2010;Cho et al, 2011). However, up to now, there was no metaanalysis comprehensively analyzing the prognostic value of thrombocytosis in cancer patients.…”

A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment

“…Cancer patients frequently present with signs of thrombosis, and these are most severe if the disease has progressed to a metastatic stage. [1][2][3][4][5][6][7] Furthermore, thrombocytopenia or the inhibition of platelet function can markedly suppress tumor metastasis. [8][9][10][11] Subsequent animal models in which specific platelet functions were altered through drug treatment or controlled genetic ablation have led to a model of platelet-supported tumor metastasis in which tumor cells enter the bloodstream (intravasation), and bind and activate platelets (cohesion) and leukocytes.…”